Background: Direct-acting oral anticoagulants (DOACs) have become the preferred drugs
for managing venous thromboembolism (VTE). Despite their advantages over vitamin K …

In clinical practice, direct oral anticoagulants (DOACs) are increasingly used for venous
thromboembolism treatment and prevention. A substantial proportion of patients with venous …

Background: Current venous thromboembolism guidelines recommend using direct oral
anticoagulants (DOACs) over warfarin regardless of obesity status; however, evidence …

Background: Direct oral anticoagulants (DOACs) are known to have similar efficacy with a
decreased risk of bleeding when compared to warfarin for the treatment of venous …

Background: While commonly prescribed today, direct oral anticoagulants (DOACs) have
historically been avoided in patients with class III obesity or a weight> 120 kg due to limited …

Background: Direct oral anticoagulants (DOACs) present a favorable alternative to warfarin
based on the decreased burden of monitoring and fewer drug and food interactions …

Background There is scarce evidence on the effectiveness and safety of recommended-
dose direct acting oral anticoagulants (DOACs) in obese patients with venous …

Background: Obesity is a well-known risk factor for venous thromboembolism (VTE),
however, obese patients are under-represented in clinical trials (1; 2). Four direct oral …

Abstract Background Direct oral anticoagulants (DOACs) are preferred over warfarin for the
treatment of venous thromboembolism (VTE) as well as atrial fibrillation (AF). The efficacy …

Four direct‐acting oral anticoagulants (DOACs)–the thrombin inhibitor dabigatran, and the
activated factor X (FXa) inhibitors apixaban, edoxaban, and rivaroxaban–are approved in …